Trials / Terminated
TerminatedNCT03332836
Multiple Ascending Dose Study of HM12460A in Type 2 Diabetes Mellitus
A Phase 1, Multiple Ascending Dose, Glucose Clamp Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HM12460A Compared to Insulin Glargine in Subjects With Type 2 Diabetes Mellitus
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- Hanmi Pharmaceutical Company Limited · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 1 multiple ascending dose (MAD) study, conducted in subjects with Type 2 Diabetes Mellitus.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | HM12460A | HM12460A is a long-acting insulin |
Timeline
- Start date
- 2017-10-25
- Primary completion
- 2019-01-30
- Completion
- 2020-09-30
- First posted
- 2017-11-06
- Last updated
- 2021-04-01
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03332836. Inclusion in this directory is not an endorsement.